Chemoradiation followed by immunotherapy for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a treatment for locally advanced esophageal cancer. You'll receive chemoradiation (chemo plus radiation) followed by a maintenance drug (a PD-1 inhibitor) to help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma.
- Your cancer is stage 3 or 4 without spread to distant organs, or spread only to lymph nodes in the neck area.
- You are 18 years or older and in generally good health (able to do daily activities).
- You have not had immunotherapy (like PD-1 inhibitors) before.
- You do not have an active autoimmune disease, uncontrolled heart problems, or active infections like hepatitis B/C or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for advanced esophageal cancer that combines targeted radiation, immunotherapy, and chemotherapy. It aims to see if skipping radiation to certain lymph nodes can improve outcomes while reducing side effects.
This trial combines an immunotherapy drug (a PD-1 inhibitor) with radiation therapy and special nutrition drinks to treat esophageal cancer that cannot be removed with surgery. The goal is to see if this combination is safe and effective in helping patients live longer and feel better.
This trial tests a new treatment for esophageal cancer that has not spread too far. It combines proton beam radiation (a precise type of radiation) with chemotherapy and immunotherapy (drugs that help your immune system fight cancer). The goal is to see if this combination is safe and effective.
This study tests a combination of chemotherapy and immunotherapy before and after standard chemoradiation for people with locally advanced esophageal squamous cell carcinoma. It aims to see if this approach can improve outcomes with manageable side effects.
This trial tests whether adding immunotherapy to standard chemoradiation can help people with unresectable locally advanced esophageal cancer. It aims to improve outcomes for those who cannot have surgery.
This trial studies giving immunotherapy (anti–PD-1) together with chemotherapy before surgery for certain locally advanced esophageal squamous cell cancer. The goal is to improve how well the tumor responds before and after the operation.
Hear when a new Esophageal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.